Abstract
Aims: Recent data have demonstrated the feasibility of therapeutic induction of coronary collateral growth (arteriogenesis); however, mechanisms of action of such therapeutic collateral stimulation in humans are unknown. The aim of this study was to evaluate potential mechanisms, especially the involvement of arteriogenesis-relevant genes. Methods and Results: A total of 52 patients were randomized into two groups: subcutaneous G-CSF (10μg/kg; n=26) or placebo (n=26). Before and after this 2-week treatment, collateral-flow index (CFI) was determined by simultaneous measurement of mean aortic, distal coronary occlusive and central venous pressure. CD34+ endothelial progenitor cells (EPC) and monocytes were quantified before, during and after treatment; gene-expression analysis of monocytes was performed with real-time polymerase chain reaction (RT-PCR). G-CSF lead to a significant increase of EPC and monocytes (4.8 and 2.6 fold, p<0.05); for both cell types, the extent of increase correlated with CFI increase (r=0.23 and 0.14, p<0.05). G-CSF also induced a change in gene expression of pro-and anti-arteriogenic genes in monocytes. Among nine assessed genes, three were found to be differentially regulated (IL8, JAK2, and PNPLa4; p<0.05). Conclusions: The mechanism of induction of collateral growth by G-CSF is related to an increase of EPC and of peripheral monocytes. It also leads to a change toward a pro-arteriogenic gene expression in peripheral monocytes.
Keywords: Arteriogenesis, collateral circulation, granulocyte-colony stimulating factor, endothelial progenitor cells, monocytes, gene expression
Current Vascular Pharmacology
Title:G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial
Volume: 11 Issue: 1
Author(s): Pascal Meier, Steffen Gloekler, Berna Oezdemir, Andreas Indermuehle, Tobias Traupe, Rolf Vogel, Stefano de Marchi and Christian Seiler
Affiliation:
Keywords: Arteriogenesis, collateral circulation, granulocyte-colony stimulating factor, endothelial progenitor cells, monocytes, gene expression
Abstract: Aims: Recent data have demonstrated the feasibility of therapeutic induction of coronary collateral growth (arteriogenesis); however, mechanisms of action of such therapeutic collateral stimulation in humans are unknown. The aim of this study was to evaluate potential mechanisms, especially the involvement of arteriogenesis-relevant genes. Methods and Results: A total of 52 patients were randomized into two groups: subcutaneous G-CSF (10μg/kg; n=26) or placebo (n=26). Before and after this 2-week treatment, collateral-flow index (CFI) was determined by simultaneous measurement of mean aortic, distal coronary occlusive and central venous pressure. CD34+ endothelial progenitor cells (EPC) and monocytes were quantified before, during and after treatment; gene-expression analysis of monocytes was performed with real-time polymerase chain reaction (RT-PCR). G-CSF lead to a significant increase of EPC and monocytes (4.8 and 2.6 fold, p<0.05); for both cell types, the extent of increase correlated with CFI increase (r=0.23 and 0.14, p<0.05). G-CSF also induced a change in gene expression of pro-and anti-arteriogenic genes in monocytes. Among nine assessed genes, three were found to be differentially regulated (IL8, JAK2, and PNPLa4; p<0.05). Conclusions: The mechanism of induction of collateral growth by G-CSF is related to an increase of EPC and of peripheral monocytes. It also leads to a change toward a pro-arteriogenic gene expression in peripheral monocytes.
Export Options
About this article
Cite this article as:
Meier Pascal, Gloekler Steffen, Oezdemir Berna, Indermuehle Andreas, Traupe Tobias, Vogel Rolf, de Marchi Stefano and Seiler Christian, G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010038
DOI https://dx.doi.org/10.2174/1570161111309010038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
Current Drug Targets Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Polyphenols-Rich Natural Products for Treatment of Diabetes
Current Medicinal Chemistry Phospholipid Transfer Protein in Diabetes, Metabolic Syndrome and Obesity
Cardiovascular & Hematological Disorders-Drug Targets 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System
CNS & Neurological Disorders - Drug Targets Assessment of Selective Homing and Contribution to Vessel Formation of Cryopreserved Peripherally Injected Bone Marrow Mononuclear Cells Following Experimental Myocardial Damage
Cardiovascular & Hematological Disorders-Drug Targets Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Artificial Intelligence as a Business Partner in Cardiovascular Precision Medicine: An Emerging Approach for Disease Detection and Treatment Optimization
Current Medicinal Chemistry Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Cyclic Nucleotide and Protein Kinase Signaling in Hypertensive Pulmonary Arterial Smooth Muscle
Current Respiratory Medicine Reviews Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Effect of Systemic Inflammation on the Function of Insulin and Glucose Metabolism in Rheumatoid Arthritis
Current Diabetes Reviews Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design